These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 26978988)
1. [Progress of mesoporous silica nanoparticles in targeting drug delivery system of antitumor drug]. Zhang HM; Mo S; Liu XQ; Han FM; Wang JY; Wang ZM Zhongguo Zhong Yao Za Zhi; 2015 Sep; 40(17):3450-5. PubMed ID: 26978988 [TBL] [Abstract][Full Text] [Related]
2. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics. Zhang W; Liu M; Liu A; Zhai G Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244 [TBL] [Abstract][Full Text] [Related]
3. Recent advances in mesoporous silica nanoparticles for antitumor therapy: our contribution. Baeza A; Manzano M; Colilla M; Vallet-Regí M Biomater Sci; 2016 May; 4(5):803-13. PubMed ID: 26902682 [TBL] [Abstract][Full Text] [Related]
4. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Vivero-Escoto JL; Slowing II; Trewyn BG; Lin VS Small; 2010 Sep; 6(18):1952-67. PubMed ID: 20690133 [TBL] [Abstract][Full Text] [Related]
5. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Pérez-Herrero E; Fernández-Medarde A Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885 [TBL] [Abstract][Full Text] [Related]
6. Mesoporous silica nanoparticles in medicine--recent advances. Mamaeva V; Sahlgren C; Lindén M Adv Drug Deliv Rev; 2013 May; 65(5):689-702. PubMed ID: 22921598 [TBL] [Abstract][Full Text] [Related]
7. Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles. Pan L; Liu J; He Q; Wang L; Shi J Biomaterials; 2013 Apr; 34(11):2719-30. PubMed ID: 23337327 [TBL] [Abstract][Full Text] [Related]
8. Thermo- and pH-responsive, Lipid-coated, Mesoporous Silica Nanoparticle-based Dual Drug Delivery System To Improve the Antitumor Effect of Hydrophobic Drugs. Feng Y; Li NX; Yin HL; Chen TY; Yang Q; Wu M Mol Pharm; 2019 Jan; 16(1):422-436. PubMed ID: 30525641 [TBL] [Abstract][Full Text] [Related]
9. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells. Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563 [TBL] [Abstract][Full Text] [Related]
10. A Review on Recent Technologies and Patents on Silica Nanoparticles for Cancer Treatment and Diagnosis. Gupta A; Kushwaha SS; Mishra A Recent Pat Drug Deliv Formul; 2020; 14(2):126-144. PubMed ID: 32928094 [TBL] [Abstract][Full Text] [Related]
11. Enzyme responsive drug delivery system based on mesoporous silica nanoparticles for tumor therapy in vivo. Liu Y; Ding X; Li J; Luo Z; Hu Y; Liu J; Dai L; Zhou J; Hou C; Cai K Nanotechnology; 2015 Apr; 26(14):145102. PubMed ID: 25789511 [TBL] [Abstract][Full Text] [Related]
12. Lactosaminated mesoporous silica nanoparticles for asialoglycoprotein receptor targeted anticancer drug delivery. Quan G; Pan X; Wang Z; Wu Q; Li G; Dian L; Chen B; Wu C J Nanobiotechnology; 2015 Feb; 13():7. PubMed ID: 25643602 [TBL] [Abstract][Full Text] [Related]
13. Enzyme-induced and tumor-targeted drug delivery system based on multifunctional mesoporous silica nanoparticles. Cheng YJ; Luo GF; Zhu JY; Xu XD; Zeng X; Cheng DB; Li YM; Wu Y; Zhang XZ; Zhuo RX; He F ACS Appl Mater Interfaces; 2015 May; 7(17):9078-87. PubMed ID: 25893819 [TBL] [Abstract][Full Text] [Related]
14. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery. Ma X; Zhao Y; Ng KW; Zhao Y Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533 [TBL] [Abstract][Full Text] [Related]
15. Advances in silica based nanoparticles for targeted cancer therapy. Yang Y; Yu C Nanomedicine; 2016 Feb; 12(2):317-32. PubMed ID: 26706409 [TBL] [Abstract][Full Text] [Related]
16. PEG-templated mesoporous silica nanoparticles exclusively target cancer cells. Morelli C; Maris P; Sisci D; Perrotta E; Brunelli E; Perrotta I; Panno ML; Tagarelli A; Versace C; Casula MF; Testa F; Andò S; Nagy JB; Pasqua L Nanoscale; 2011 Aug; 3(8):3198-207. PubMed ID: 21725561 [TBL] [Abstract][Full Text] [Related]
17. Mesoporous Silica Nanoparticles in Cancer Therapy: Relevance of the Targeting Function. Pasqua L; Leggio A; Sisci D; Andò S; Morelli C Mini Rev Med Chem; 2016; 16(9):743-53. PubMed ID: 26996622 [TBL] [Abstract][Full Text] [Related]
18. Structure-property relationships in manganese oxide--mesoporous silica nanoparticles used for T1-weighted MRI and simultaneous anti-cancer drug delivery. Chen Y; Chen H; Zhang S; Chen F; Sun S; He Q; Ma M; Wang X; Wu H; Zhang L; Zhang L; Shi J Biomaterials; 2012 Mar; 33(7):2388-98. PubMed ID: 22177841 [TBL] [Abstract][Full Text] [Related]
19. New insights towards mesoporous silica nanoparticles as a technological platform for chemotherapeutic drugs delivery. Sábio RM; Meneguin AB; Ribeiro TC; Silva RR; Chorilli M Int J Pharm; 2019 Jun; 564():379-409. PubMed ID: 31028801 [TBL] [Abstract][Full Text] [Related]
20. Targeted Mesoporous Silica Nanocarriers in Oncology. Baeza A; Vallet-Regi M Curr Drug Targets; 2018 Feb; 19(3):213-224. PubMed ID: 27262488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]